The multi-departmental and multi-categorical General Clinical Research Center at The New York Hospital-Cornell Medical Center serves as the focal point for Cornell University Medical College's programs in clinical investigation and in clinical research training. This proposal requests five years of continued support for adult component of the Center, wherein normal function and disease mechanisms in humans can be studied in an optimal setting for controlled clinical investigations. The Center provides a discrete in-patient research wards for 12 adults. A new out-patient unit for adults will provide an important alternative for the study of ambulatory research subjects. Adult core laboratory provide non-routine, quality-controlled analyses including mass spectrometry for a diverse number of investigators and projects. In addition to the scientific faculty of this institution, the facility is also available to clinical investigators at adjoining categorical hospitals, as an in-patient research resources within a high technology, tertiary-care general hospital. Current and projected projects involve both basic and clinical scientific, and include studies in the areas of endocrinology and metabolism, hypertension, cardiology, hematology, infectious diseases, rheumatology, cancer, immunology, genetics, nephrology, surgery, obstetrics, neurology, pharmacology, and psychiatry. Diseases under study utilizing the GCRC resource are complex and multi-disciplinary in scope, and all are of considerable biological, medical, and/or public health significance.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000047-34
Application #
2280898
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1977-12-01
Project End
1996-11-30
Budget Start
1993-12-30
Budget End
1994-11-30
Support Year
34
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
de Simone, Giovanni; Wang, Wenyu; Best, Lyle G et al. (2017) Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. Cardiovasc Diabetol 16:64
Gerber, Linda M; Sievert, Lynnette L; Schwartz, Joseph E (2017) Hot flashes and midlife symptoms in relation to levels of salivary cortisol. Maturitas 96:26-32
De Marco, Marina; Gerdts, Eva; Mancusi, Costantino et al. (2017) Influence of Left Ventricular Stroke Volume on Incident Heart Failure in a Population With Preserved Ejection Fraction (from the Strong Heart Study). Am J Cardiol 119:1047-1052
Schachterle, William; Badwe, Chaitanya R; Palikuqi, Brisa et al. (2017) Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nat Commun 8:13963
Haring, Bernhard; Wang, Wenyu; Fretts, Amanda et al. (2017) Red meat consumption and cardiovascular target organ damage (from the Strong Heart Study). J Hypertens 35:1794-1800
Beheshtian, Azadeh; Shitole, Sanyog G; Segal, Alan Z et al. (2016) Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 253:47-53
Leung, Vivien; Chiu, Ya-Lin; Kotler, Donald P et al. (2016) Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation. HIV Clin Trials 17:55-62
de Simone, Giovanni; Roman, Mary J; De Marco, Marina et al. (2015) Hemodynamic Correlates of Abnormal Aortic Root Dimension in an Adult Population: The Strong Heart Study. J Am Heart Assoc 4:e002309
Bhatia, Rajeev; Lesser, Daniel J; Oliveira, Flavia G S A et al. (2015) Body Fat Composition: A Predictive Factor for Sleep Related Breathing Disorder in Obese Children. J Clin Sleep Med 11:1039-45
Ocean, Allyson J; Christos, Paul; Sparano, Joseph A et al. (2014) Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs 32:542-8

Showing the most recent 10 out of 370 publications